Savara Inc.
SVRA
$0.07
Change (1 day)
$5.70
Year High
$2.82
Year Low
Categories
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Savara Inc. (SVRA) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 1.01 M | 153 K | 37.19 M | 177.56 M | 165.95 M |
| 2022 | 954 K | -25,958,000 | 32 M | 139.78 M | 128.95 M |
| 2021 | 1.14 M | -8,221,000 | 32.1 M | 176.6 M | 165 M |
| 2020 | 1.7 M | 2.4 M | 33.36 M | 97.75 M | 85.12 M |
| 2019 | 1.62 M | -24,252,000 | 34.51 M | 136.2 M | 124.07 M |